[Prevalence of use of hormone replacement therapy in women participating in a breast cancer screening program].
OBJECTIVE
The purpose of the study was to determine the prevalence and type of hormone replacement therapy (HRT) in participants in a breast cancer screening program (BCSP) in Barcelona.


METHODS
Prevalence of use of HRT was obtained through a survey. Information about type of HRT, gynecological history and socioeconomic and educational level was collected. Prevalence was calculated with its corresponding 95% confidence interval.


RESULTS
From May 2001 to June 2005 there were 21835 participants in the BCSP with a mean age of 57,6 years. Most of the participants were postmenopausal (86,7%). Confirmed prevalence of use of HRT was 5,2%(CI95% 5,3-6,0) with a greater use among women aged 55 to 59 years. The most frequent types of HRT were tibolone (39,5%) followed by combined estrogens plus progestin (30,4%). Higher education was associated with a higher use of HRT. Neither the use or the type of HRT influenced the results of the screening program.


CONCLUSIONS
Prevalence of use of HRT was 5,2% in this study. The most frequently used agents were tibolone and combined estrogens plus progestin.
Martínez-Pino
Isabel
I
Servicio de Epidemiología Clínica y Salud Pública, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, España. imartinezpino@gmail.com
Puig
Teresa
T
Quintana
María Jesús
MJ
Solà
Judit
J
Bonfill
Xavier
X
D000368:Aged; D018931:Antineoplastic Agents, Hormonal; D001943:Breast Neoplasms / Q000517:prevention & control*; D016001:Confidence Intervals; D003627:Data Interpretation, Statistical; D015914:Estrogen Replacement Therapy; D004967:Estrogens; D005260:Female; D006306:Health Surveys; D020249:Hormone Replacement Therapy; D006801:Humans; D008403:Mass Screening; D008593:Menopause; D008875:Middle Aged; D009652:Norpregnenes; D017698:Postmenopause; D015995:Prevalence; D011372:Progestins; D012959:Socioeconomic Factors; D013030:Spain; D011795:Surveys and Questionnaires
D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D009652:Norpregnenes; D011372:Progestins; C027385:tibolone